Publication details
Postavení panitumumabu v algoritmu léčby kolorektálního karcinomu
| Title in English | Panitumumab in colorectal cancer treatment algorithm |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| Citation | |
| Field | Oncology and hematology |
| Keywords | panitumumab, chemotherapy, metastatic colorectal cancer |
| Description | Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It is commonly used as a single agent in third line therapy in patients with metastatic colorectal cancer (mCRC) and wild type KRAS tumour status whose disease progressed after standard chemotherapy. The effect of addition of panitumumab to FOLFOX in the first line and to FOLFIRI in second line therapy was demonstrated in randomised phase III trials. Safety profile of panitumumab is good. Adverse events were comparable across arms with the exception of known toxicities associated with anti- EGFR therapy. |